EN DE
Watch ONESOURCE SPECIALTY PHARMA LTD for free: we tell you when fair value or trend changes.
Data-driven stock valuation

ONESOURCE SPECIALTY PHARMA LTD (ONESOURCE) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of ONESOURCE SPECIALTY PHARMA LTD stock ₹249, price ₹1,613, that is 84.6% below the price, quality 26 out of 100. Rating: strongly overvalued. Calculated from audited financials with 2 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare IN

OS ONESOURCE SPECIALTY PHARMA LTD logo Thin data Nov 10, 2026

ONESOURCE SPECIALTY PHARMA LTD

ONESOURCE · NSE

Far too expensive (fair value 85% below the price), weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Low debt 
Revenue last quarter +38% vs. a year ago. 
Expensive Growth (revenue 3y +232.4 %/yr in INR) 
Mixed vs. peers (5/11) 
Fair value ₹248.77 · Strongly overvalued 
Quality 26/100 
Falling price (downtrend) 
Loss-making · -0.1% net margin (TTM) 
Negative free cash flow 
Narrow moat 28/100
Thin data 
Extreme value
Watch ONESOURCE SPECIALTY PHARMA LTD for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

₹2,198 ₹1,114 Fair Value ₹248.77 Jan 2025 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

22‑month range ₹1,114 – ₹2,198 · fair‑value band ₹155.92 – ₹341.62 · the ₹1,613 price screens above the ₹248.77 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow ONESOURCE SPECIALTY PHARMA in your weekly email

Every Wednesday you see whether ONESOURCE SPECIALTY PHARMA is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

OneSource Specialty Pharma Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biological drug products in various injectable formats in India, Ireland, the United States, and internationally.

Show moreShow less

The company provides end-to-end contract development and manufacturing operations (CDMO) services across various phases of preclinical and clinical development and commercial supply of biologics.

It also offers drug-devices, including prefilled syringes, dial and push variable and fixed dose pen injectors, pull push fixed dose pens, and autoinjectors; sterile injectables; soft gelatin capsules; and biologics solutions for microbial and mammalian cell line biopharmaceuticals, cell and gene therapy, and RNA products.

The company was formerly known as Stelis Biopharma Limited and changed its name to OneSource Specialty Pharma Limited in February 2024. OneSource Specialty Pharma Limited was incorporated in 2007 and is based in Bengaluru, India.

Stock analysis

ONESOURCE SPECIALTY PHARMA LTD (ONESOURCE) currently trades at ₹1,613, while our model-based Fair Value estimate is ₹248.77, 85% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 2 models at a data quality of 92/100, which puts the data coverage at low.

Scenario range: ₹155.92 (bear) to ₹341.62 (bull), the price of ₹1,613 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 26/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

ONESOURCE SPECIALTY PHARMA LTD reported revenue of ₹14.2B in FY2026 versus ₹387M in FY2023, a compound +232.4%/yr. Reported net income was −₹738M in FY2026.

Key figures

Market cap ₹185B (≈ $2.0B) Small · P/S ratio 10.8 · EPS (TTM) ₹−0.1500 · Net margin −0.1% · Return on equity 0.0% · Return on assets (EBIT) −5.0% (4-year average) · Operating margin 17.3% · Revenue (TTM) ₹16.8B.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (medium confidence).

What moves the price

The share trades about 14% below its 52-week high and 45% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −85%, ONESOURCE screens richer than that median.

Fair Value models

Bear ₹155.92 Fair Value ₹248.77 Bull ₹341.62
Price ₹1,613 · Downside -84.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EV/EBITDA ₹155.92 ₹248.77 ₹341.62 66
NCAV (Graham) ₹22.86 ₹30.64 ₹45.72 54
All 2 models by family
Multiples
EV/EBITDA ₹155.92 ₹248.77 ₹341.62 66
Asset-Based
NCAV (Graham) ₹22.86 ₹30.64 ₹45.72 54

Open the full fair value analysis →

Quality Score breakdown

Overall quality 26/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 8
How much profit the company makes from its sales and capital
Quality Growth 22
Are margins and returns getting better?
Cashflow 22
Do the profits arrive as real cash?
Financial strength 59
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 33
How calm the share price moves, does not count
Price momentum 29
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 46
Distance to the 52-week high, does not count
New shares 63
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 32/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−1.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+232.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−557.6% (2023) → 1.8% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

ONESOURCE screens overvalued: fair value 85% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare ONESOURCE SPECIALTY PHARMA LTD with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 848 stocks

Beats the industry median on 4/10 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 26 · Bottom 25%
Fair Value upside −84.6% · Bottom 25%
Profitability
Return on assets −0.9% · Top 25%
Net margin (12 months) −0.1% · Above median
Operating margin (12 months) 17.3% · Above median
Growth and dividend
Revenue growth (quarter YoY) 37.6% · Top 25%
Balance sheet
Debt / equity 0.10× · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 3.17× · Pricier than median
P/S (12 months) 10.99× · Pricier than median
EV/EBITDA 56.5× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 1
FUTURE (revenue growth)100 · sector 36
PAST (return on equity)0 · sector 0
HEALTH (low debt)95 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $952.40 $1,275 +34% vs ONESOURCE
Vertex Pharmaceuticals Incorporated VRTX $537.79 $592.46 +10% vs ONESOURCE
Samsung Biologics Co 207940 1,423,000 KRW 1,552,100 KRW +9% vs ONESOURCE
argenx SE ARGX $950.95 $908.40 −4% vs ONESOURCE
CSL Limited CSL A$199.55 A$186.49 −7% vs ONESOURCE
Moderna, Inc MRNA $215.27 $135.64 −37% vs ONESOURCE
BeOne Medicines AG 6160 HK$249.40 HK$152.92 −39% vs ONESOURCE
Revolution Medicines, Inc RVMD $166.87 $88.78 −47% vs ONESOURCE
Celltrion, Inc 068270 214,500 KRW 74,945 KRW −65% vs ONESOURCE
Royalty Pharma plc RPRX $68.53 $19.01 −72% vs ONESOURCE

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

ONESOURCE SPECIALTY PHARMA LTD: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "ONESOURCE SPECIALTY PHARMA LTD Fair Value". https://www.fairvalue-calculator.com/stock/ONESOURCE

Frequently asked questions

Is ONESOURCE SPECIALTY PHARMA LTD (ONESOURCE) overvalued or undervalued?
As of Nov 10, 2026, our model estimates a fair value of ₹248.77 versus a price of ₹1,613, about 85% lower (overvalued).
What is the fair value of ONESOURCE?
Our model-based fair value for ONESOURCE SPECIALTY PHARMA LTD is ₹248.77 (as of Nov 10, 2026), built from audited fundamentals. The current price: ₹1,613.
What is the quality score of ONESOURCE?
ONESOURCE SPECIALTY PHARMA LTD has a Quality Score of 26/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for ONESOURCE SPECIALTY PHARMA LTD (ONESOURCE)?
Our model-based price target is the fair value of ₹248.77 (as of Nov 10, 2026) from 2 valuation models. Cautious scenario ₹155.92, optimistic scenario ₹341.62. It is a calculation from audited fundamentals, not an analyst target.
What is the ONESOURCE SPECIALTY PHARMA LTD stock forecast for 2026?
Our models put fair value at ₹248.77, about 85% lower versus a price of ₹1,613 (overvalued). Cautious scenario ₹155.92, optimistic scenario ₹341.62. The calculation is refreshed regularly with new filings.
What is the revenue of ONESOURCE SPECIALTY PHARMA LTD (ONESOURCE)?
ONESOURCE SPECIALTY PHARMA LTD reported trailing-twelve-month revenue of about ₹16.8B (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of ONESOURCE SPECIALTY PHARMA LTD (ONESOURCE)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For ONESOURCE SPECIALTY PHARMA LTD it is ₹248.77 per share (as of Nov 10, 2026), against a price of ₹1,613. It is the blended result of 2 valuation models in 2 families (Multiples, Asset-Based).
Is ONESOURCE SPECIALTY PHARMA LTD stock overvalued or undervalued in 2026?
As of Nov 10, 2026, ONESOURCE trades above its calculated fair value: price ₹1,613, fair value ₹248.77, a gap of about −85% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ONESOURCE?
No. The price is what the market pays today (₹1,613); the fair value is what the company's own numbers justify (₹248.77). For ONESOURCE SPECIALTY PHARMA LTD the two are ₹1,364 per share apart. That gap is exactly why we show both numbers side by side.
How much is ONESOURCE SPECIALTY PHARMA LTD worth?
The market values ONESOURCE SPECIALTY PHARMA LTD at about ₹185B (market capitalisation, as of Nov 10, 2026). Per share that is ₹1,613; our models calculate a fair value of ₹248.77 per share.
What do the bullish and bearish scenarios say about ONESOURCE?
Our models span a range for ONESOURCE SPECIALTY PHARMA LTD: cautious scenario ₹155.92, base ₹248.77, optimistic ₹341.62 per share (as of Nov 10, 2026, price ₹1,613). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of ONESOURCE SPECIALTY PHARMA LTD (ONESOURCE)?
Balance-sheet figures for ONESOURCE SPECIALTY PHARMA LTD (as of Nov 10, 2026): return on equity 0.0%, debt of 0.10 per unit of equity. They feed the Quality Score of 26/100, which measures business quality independently of the share price.
How far is ONESOURCE from its 52-week high?
ONESOURCE SPECIALTY PHARMA LTD trades at ₹1,613, about 14% below its 52-week high of ₹1,867 and 45% above the low of ₹1,114 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of ₹248.77 is for.
Which stocks are comparable to ONESOURCE SPECIALTY PHARMA LTD?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is ONESOURCE SPECIALTY PHARMA LTD stock attractive at the current price?
The data as of Nov 10, 2026: price ₹1,613, calculated fair value ₹248.77 (−85%), Quality Score 26/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ONESOURCE calculated?
We run ONESOURCE SPECIALTY PHARMA LTD through 2 models from 2 families: Multiples, Asset-Based. Every model gets the same audited fundamentals; the fair value of ₹248.77 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. ONESOURCE SPECIALTY PHARMA LTD itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of ONESOURCE SPECIALTY PHARMA LTD (ONESOURCE)?
The closing price on Nov 16, 2026 was ₹1,613. Our model-based fair value is ₹248.77, about 85% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with ONESOURCE SPECIALTY PHARMA LTD right now?
The price sits above even our optimistic bull case (₹341.62). The favourable scenario is already priced in. Weak quality (26/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (₹155.92 to ₹341.62) leaves room in how you read the outcome.

Key figures of ONESOURCE SPECIALTY PHARMA LTD

How large is the market capitalisation of ONESOURCE SPECIALTY PHARMA LTD (ONESOURCE)?
The market capitalisation of ONESOURCE SPECIALTY PHARMA LTD is ₹185B (≈ $2.0B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of ONESOURCE SPECIALTY PHARMA LTD (ONESOURCE)?
The price-to-sales ratio of ONESOURCE SPECIALTY PHARMA LTD is 10.8 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of ONESOURCE SPECIALTY PHARMA LTD (ONESOURCE)?
Earnings per share at ONESOURCE SPECIALTY PHARMA LTD are ₹−0.1500. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of ONESOURCE SPECIALTY PHARMA LTD (ONESOURCE)?
The net margin of ONESOURCE SPECIALTY PHARMA LTD is −0.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of ONESOURCE SPECIALTY PHARMA LTD (ONESOURCE)?
The return on equity (ROE) of ONESOURCE SPECIALTY PHARMA LTD is 0.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of ONESOURCE SPECIALTY PHARMA LTD (ONESOURCE)?
On an EBIT basis the return on assets of ONESOURCE SPECIALTY PHARMA LTD is −5.0% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of ONESOURCE SPECIALTY PHARMA LTD (ONESOURCE)?
The operating margin of ONESOURCE SPECIALTY PHARMA LTD is 17.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at ONESOURCE SPECIALTY PHARMA LTD (ONESOURCE)?
Revenue at ONESOURCE SPECIALTY PHARMA LTD is growing 37.6% versus a year earlier (3y avg +232%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at ONESOURCE SPECIALTY PHARMA LTD (ONESOURCE)?
Earnings per share at ONESOURCE SPECIALTY PHARMA LTD are growing 451% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does ONESOURCE SPECIALTY PHARMA LTD (ONESOURCE) generate?
The free cash flow of ONESOURCE SPECIALTY PHARMA LTD is −₹6.8B (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does ONESOURCE SPECIALTY PHARMA LTD (ONESOURCE) carry?
The net debt of ONESOURCE SPECIALTY PHARMA LTD is ₹14.1B (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch ONESOURCE SPECIALTY PHARMA LTD in the live analysis

One click puts ONESOURCE SPECIALTY PHARMA LTD on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.